India's contribution to the $65-$70 billion US generics market is only about 10 percent, says pharma trade body Pharmexcil, and the cost of production here is 40 percent lower than in North America and Europe
Speaking to CNBC-TV18, Krishna Kumar Karwa, MD and CEO at Emkay Global Financial Services, said pharma and IT could give relatively better returns in 12-18 months.